{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-061412","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2026-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.187669+00:00","generated_at":"2026-05-16T01:26:38.800650+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Atossa enters $50M ATM equity offering with Rodman & Renshaw; terminates Jefferies facility","bullets":["ATM agreement allows up to $50M in common stock sales; company pays 3% commission to sales agent.","Proceeds intended for clinical development, working capital, and general corporate purposes.","Prior Jefferies ATM agreement terminated with no sales made; no termination penalties incurred.","Company not obligated to sell any shares; may suspend or terminate the arrangement at any time.","Offering registered under effective S-3 shelf (filed May 2024); prospectus supplement filed Feb 20, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-061412","json":"https://secwatch.observer/filing/0001193125-26-061412.json","markdown":"https://secwatch.observer/filing/0001193125-26-061412.md","text":"https://secwatch.observer/filing/0001193125-26-061412.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526061412/0001193125-26-061412-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526061412/d100198d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:26:38.800650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62653bd05a11b4d4e9b5975e1228e95dfaf4bfa9","claim":"ATOSSA THERAPEUTICS, INC. terminated Prior Agreement with Jefferies LLC (effective 2026-02-19).","evidence_excerpt":"On February 19, 2026, the Company delivered written notice to Jefferies LLC indicating that it is terminating the Open Market Sale Agreement SM (the “Prior Agreement”) by and between the Company and Jefferies LLC, dated November 19, 2024, effective as of February 19, 2026.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526061412/0001193125-26-061412-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Jefferies LLC"},{"label":"Effective","value":"2026-02-19"}],"fact_type":"material_agreement"},{"claim_id":"f4f4a07c6fb1f2be3ea187b299aca397de5c920b","claim":"ATOSSA THERAPEUTICS, INC. entered into Sales Agreement with Rodman & Renshaw LLC valued at up to $50,000,000 (effective 2026-02-20).","evidence_excerpt":"On February 20, 2026, Atossa Therapeutics, Inc. (the “Company”) entered into the At the Market Offering Agreement, dated February 20, 2026 (the “Sales Agreement”), with Rodman & Renshaw LLC (the “Sales Agent”), pursuant to which the Company may offer and sell from time to time up to $50,000,000 of shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526061412/0001193125-26-061412-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Rodman & Renshaw LLC"},{"label":"Value","value":"up to $50,000,000"},{"label":"Effective","value":"2026-02-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}